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demonstrate the impact of population characteristics on
mean antipsychotic dose. We will compare results using
different techniques to adjust average dose for population
differences. Techniques presented will include stratifica-
tion, limiting study population variation, and various mul-
tivariate regression coding and modeling strategies. We
discuss which techniques provide the greatest generaliz-
ability and the most valid comparisons.
WTG6
MAKING DECISIONS ABOUT
ANTIBIOTIC RESISTANCE
Davey PG
MEMO, Dundee, Scotland
WORKSHOP OBJECTIVE: Antibiotic resistance is an in-
creasing global problem and there is no doubt that it is
caused by antibiotic prescribing. Nonetheless, most pre-
scribing necessarily occurs at a time when it is uncertain
whether the patient has bacterial infection, never mind what
organism is causing the infection. The prescriber faces two
problems: 1) Which drug should I select in order to maxi-
mize this patient’s chance of recovery? (e.g., at what level of
trimethoprim resistance in Escherichia coli should I switch
to quinolones as my first line treatment for simple cystitis in
primary care?). 2) What impact does my choice of prescrib-
ing have on the prevalence of antibiotic resistance? (e.g., if I
recommend carbapenems for first-line treatment of sus-
pected intra-abdominal infection, will I be storing up future
trouble by increasing the prevalence of carbapenem resis-
tant bacteria in the hospital?). These two questions highlight
a conflict of interest that is at the heart of all healthcare de-
cision-making (Sabin, Br Med J 1998; 317:1002–4): the
competing duties of fidelity (to the individual patient) versus
stewardship (prudent allocation of scarce resources).
PARTICIPANTS WHO SHOULD ATTEND: Research-
ers and decision-makers with responsibility for antimi-
crobial prescribing. However, the issues raised are rele-
vant to the whole debate about priority setting.
The workshop will focus on two contrasting problems:
management of simple cystitis in primary care and man-
agement of intra-abdominal sepsis in hospitals. A generic
decision tree and influence diagram will be used as the
basis for discussion. Participants will be asked to identify
the key chance nodes that should influence decision-mak-
ing, and consider potential sources of information about
probabilities and utilities. The authors will share infor-
mation derived from two ongoing research projects.
WDM1
CURRENT COMPUTER SOFTWARE 
AND HARDWARE OPTIONS IN
PHARMACOECONOMICS: SPREADSHEETS, 
DECISION ANALYSIS, INTERNET, AND 
EDUCATIONAL TOOLS
McGhan WF
University of the Sciences in Philadelphia, Philadelphia, PA, USA
WORKSHOP OBJECTIVE: At the end of this session,
participants will be able to compare and contrast various,
current software and hardware options for pharmacoeco-
nomics and outcomes research.
PARTICIPANTS WHO WOULD BENEFIT: This ses-
sion is intended for individuals who have a basic under-
standing of the concepts used in pharmacoeconomic
analyses who wish to learn more about computer soft-
ware and hardware options.
Pharmacoeconomic analysis software programs should al-
low data and results to be examined from different policy
perspectives: 1) patient, 2) provider, 3) hospital, 4) payer,
and 5) society. Software models should also allow the as-
sessment of the healthcare interventions or services from
different quantitative perspectives: 1) cost of illness, 2)
cost-minimization, 3) cost-benefit, 4) cost-effectiveness,
and 5) cost-utility. Decision trees and sensitivity analysis
software will be reviewed. Programming options include
spreadsheet macros, visual basic, and Web page authoring
tools. Software programs will be demonstrated that can be
utilized on various hardware platforms including desk-
tops, laptops, and remote handhelds. Software applica-
tions can assist in analyzing data, present findings, or edu-
cate providers and patients. More software is becoming
available that facilitates assessment and incorporation of
patient preferences and quality of life scores into therapy
decision-making for treatment protocol development and
interfacing at the patient’s bedside. Questions that should
be asked in evaluating software include: How much of the
model is built on rigorous clinical trial data? Has the soft-
ware been peer reviewed and field tested? Are any ques-
tionnaires valid and reliable? Is the information well ref-
erenced? Can sensitivity and incremental analyses be
performed? Software and hardware options will be dem-
onstrated. Pros and cons of diverse analytical and soft-
ware approaches will be examined.
WMM1
IS THE CURRENT RELIANCE ON THE
MARKOV ASSUMPTION IN ECONOMIC
MODELS JUSTIFIED?
Caro JJ, Huybrechts KF
Caro Research, Boston, MA, USA
WORKSHOP OBJECTIVE: The objective of this work-
shop is to demonstrate why the willingness to rely on the
Markov restriction in economic models may not be justi-
fied and to suggest alternative approaches.
PARTICIPANTS WHO WOULD BENEFIT: Research-
ers involved in the development of health economic mod-
els, as well as those responsible for evaluating models.
Markov processes were first described by the Russian
mathematician Markov at the beginning of this century.
His intent was to generalize classical properties of se-
quences of independent random variables to sequences
not fulfilling the independence assumption. A Markov
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process was defined as the state function of some system
whose state at a future time can be probabilistically pre-
dicted from its present state, in a way that cannot be im-
proved by taking account of previous states—known as
the Markov property. Nowadays, many economic mod-
els use the Markov technique and are limited by its prop-
erty. The correctness of this approach is questionable, as
will be addressed in the workshop. In an attempt to ad-
here to a well-known technique, many researchers tend
to ignore the memory component inherent to the disease.
Although this major simplification makes the develop-
ment and computation of these models easier, it often de-
parts substantially from reality. Others circumvent the
consequences of the core philosophy behind the tech-
nique and simulate memory by creating tunnel states.
This only provides a partial, suboptimal solution, how-
ever. We feel researchers should urgently shift their focus
to other modeling approaches better suited to the specific
research question. Although more complicated, the devel-
opment of memory-based models is clearly feasible with
today’s computer capabilities, as we will illustrate based
on our own experience.
WMM2
ECONOMIC EVALUATION OF PROSPECTIVE 
MULTINATIONAL CLINICAL TRIALS: A 
MODELING APPROACH
Hux M1, Weinstein M1,2, Torrance G1,3
1Innovus Research Inc., Burlington, ON, Canada; 2Harvard 
School of Public Health, Boston MA, USA; 3McMaster 
University, Hamilton, ON, Canada
WORKSHOP OBJECTIVE: A modeling approach to the
use of data from a multinational clinical trial for eco-
nomic evaluation of a new product in a specific partici-
pating country is described. Treatment effectiveness is es-
timated based on efficacy data using all participating
countries. Costs to a relevant healthcare perspective and
to society are modeled based on clinical response to treat-
ment combined with health resource use in the specific
country of interest. Costs for patients dropping off study
treatment may be estimated from other sources and used
in the model for a more comprehensive estimate of total
costs and consequences.
PARTICIPANTS WHO WOULD BENEFIT: Research-
ers involved with the design or conduct of economic eval-
uations related to prospective clinical trials.
In many countries, economic evaluation of new products
is required or has come to be expected by regulatory and
clinical audiences rapidly after product launch. Multina-
tional clinical trials powered to estimate efficacy and
safety against a standard treatment using data from all
countries combined have become common in phase III of
the drug development process. Many researchers are us-
ing this valuable opportunity to collect high quality RCT
data on health resource use, quality of life and patient
preferences. In contrast to efficacy and safety informa-
tion, it may not be possible to directly combine health re-
source use from several countries due to between-country
differences in healthcare systems, treatment practice pat-
terns, and healthcare seeking behavior. We describe the
use of a decision tree model to structure the evaluation
with estimates of treatment efficacy, safety, and resource
use collected from the clinical trial.
WMS1
ESTIMATING MEDICAL COSTS FROM 
INCOMPLETE FOLLOW-UP DATA
Polsky D, Glick H
University of Pennsylvania, Philadelphia, PA, USA
WORKSHOP OBJECTIVE: The purpose of this work-
shop will be to develop skills in the analysis of cost data
at the patient level when incomplete follow-up or drop-
outs result in censored cost data. We will identify the
conditions when univariate summary data are unbiased
as well as the conditions when various multivariate tech-
niques using regression analysis and survival analysis are
required for unbiased estimates.
PARTICIPANTS WHO WOULD BENEFIT: Research-
ers and analysts involved in the methodological and ana-
lytic aspects of pharmacoeconomic studies as well as
those who want to increase their understanding of the lit-
erature of economic evaluation in clinical trials.
As treatment costs are increasingly determined from indi-
vidual level cost data, analysts have become increasingly
aware of the difficulty in characterizing medical costs for
all individuals for comparable durations of time. It is
common for data on resource use and/or costs not to
cover the entire duration of the study. This may be due to
the final design (e.g., rolling admission and a fixed stop-
ping date), limited commitment to the collection of eco-
nomic data, or individuals dropping out of the economic
study or the administrative database. Different models
for analyzing costs should be used depending on the an-
swers to the following questions: Are the dropouts con-
centrated among the most severe patients? Are the rea-
sons for dropouts related to the treatment drug? Could
the dropouts be related to some unmeasured phenome-
non that is correlated with costs? Is death a possibility
among the dropouts? Practical guidance will be provided
for applying the appropriate methods by critically re-
viewing the statistical models for addressing these issues
using a resent AIDS trial as an example.
WMD1
DATA COLLECTION METHODS FOR
RESOURCE UTILIZATION: CHOOSING
THE RIGHT APPROACH
Crawford B, Evans C
MAPI Values, Boston, MA, USA
WORKSHOP OBJECTIVE: The purpose of this work-
shop will be to develop a deeper understanding of vari-
